Ambu

Ambu

AMBU-B.CO
Ballerup, Denmark· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $200M

Market Cap: $2.6BFounded: 1937HQ: Ballerup, Denmark

Overview

Ambu is a global leader in single-use medical devices, having fundamentally transformed procedural standards by introducing the world's first single-use flexible video endoscope in 2009. Its strategy centers on an integrated platform of single-use visualization tools for airway management and endoscopy, driving growth by addressing cross-contamination risks, high reprocessing costs, and workflow inefficiencies. The company is publicly traded and leverages its deep clinical evidence and platform stickiness to expand its market leadership.

Airway ManagementPulmonologyGastroenterologyUrologyENT (Otorhinolaryngology)AnaesthesiaEmergency Medicine

Technology Platform

An integrated visualization and data management platform (aView 2 Advance / aBox 2) that serves as a central hub for a full suite of single-use endoscopes and airway management devices, enabling multi-device interoperability, Dual View functionality, and EHR connectivity.

Funding History

2
Total raised:$200M
Debt$200M
IPOUndisclosed

Opportunities

The global shift towards single-use devices for infection control and operational efficiency represents a multi-billion dollar, high-growth market.
Ambu's first-mover advantage, broad integrated platform, and strong clinical evidence base position it to capture significant share across multiple medical specialties and geographic regions.

Risk Factors

Intense competition from large medtech incumbents launching rival single-use products poses pricing and market share risks.
The environmental impact of single-use devices presents a growing ESG challenge that requires proactive management through design and recycling initiatives.

Competitive Landscape

Ambu competes with traditional reusable endoscopy giants (Olympus, Karl Storz) now launching single-use products, and with niche single-use specialists in specific segments. Its competitive edge lies in its dedicated single-use focus, broadest integrated platform, and extensive clinical evidence supporting its value proposition.

Company Timeline

1937Founded

Founded in Ballerup, Denmark

2017IPO

Initial Public Offering

2021Debt

Debt: $200.0M